Umair Ahmed Bargir

Dr. Umair Ahmed Bargir

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JAJahnavi Aluri
Jahnavi Aluri
MDMukesh Desai
Mukesh Desai
MGMaya Gupta
Maya Gupta
ADAparna Dalvi
Aparna Dalvi
ATAntony Terance
Antony Terance
MMManisha Madkaikar
Manisha Madkaikar
Severe combined immunodeficiency (SCID) represents one of the most severe forms of primary immunodeficiency (PID) disorders characterized by impaired cellular and humoral immune responses. Here, we report the clinical, immunological, and molecular findings in 57 patients diagnosed with SCID from India. Majority of our patients (89%) presented within 6 months of age. The most common clinical manifestations observed were recurrent pneumonia (66%), failure to thrive (60%), chronic diarrhea (35%), gastrointestinal infection (21%), and oral candidiasis (21%). Hematopoietic Stem Cell Transplantation (HSCT) is the only curative therapy available for treating these patients. Four patients underwent HSCT in our cohort but had a poor survival outcome. Lymphopenia (absolute lymphocyte counts/μL <2,500) was noted in 63% of the patients. Based on immunophenotypic pattern, majority of the cases were T−B− SCID (39%) followed by T−B+ SCID (28%). MHC class II deficiency accounted for 10.5% of our patient group. A total of 49 patients were molecularly characterized in this study and 32 novel variants were identified in our cohort. The spectrum of genetic defects in our cohort revealed a wide genetic heterogeneity with the major genetic cause being RAG1/2 gene defect (n = 12) followed by IL2RG (n = 9) and JAK3 defects (n = 9). Rare forms of SCID like Purine nucleoside phosphorylase (PNP) deficiency, reticular dysgenesis, DNA-Protein Kinase (DNA-PKcs) deficiency, six cases of MHC class II deficiency and two ZAP70 deficiency were also identified in our cohort. Fourteen percent of the defects still remained uncharacterized despite the application of next generation sequencing. With the exception of MHC class II deficiency and ZAP70 deficiency, all SCID patients had extremely low T cell receptor excision (TRECs) (<18 copies/μL).

14 August 2021 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
MKMadhura G. Kelkar
Madhura G. Kelkar
UBUmair Ahmed Bargir
Umair Ahmed Bargir
RYReetika Yadav
Reetika Yadav
MGMaya Gupta
Maya Gupta
ADAparna Dalvi
Aparna Dalvi
MMManisha Madkaikar
Manisha Madkaikar

31 July 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
GHGouri P. Hule
Gouri P. Hule
UBUmair Ahmed Bargir
Umair Ahmed Bargir
MKManasi Kulkarni
Manasi Kulkarni
PKPriyanka Kambli
Priyanka Kambli
PTPrasad Taur
Prasad Taur
MMManisha Madkaikar
Manisha Madkaikar
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, the enzyme complex responsible for reactive oxygen species (ROS) production, is defective in chronic granulomatous disease (CGD) patients. This enzyme helps in antimicrobial host defense by phagocytes. CGD patients are unable to form neutrophil extracellular traps (NETs), which are composed of granule-derived proteins from neutrophils decorated with decondensed chromatin. Mitochondria have gained attention, being a rich source of flavochrome enzymes due to the presence of several sites for superoxide production. Recently, PPARγ agonists, a mitochondrial ROS inducer, induce mitochondrial ROS formation post-treatment in murine NADPH oxidase knockout models. Mitochondrial ROS is also essential for NOX-independent NETosis. Our study for the first time detects induction of NETosis independent of NADPH oxidase post-treatment with agonists such as pioglitazone and rosiglitazone in CGD subjects. Neutrophils isolated from CGD subjects were treated with pioglitazone and rosiglitazone. After treatment, qualitative analysis of NET formation was done using confocal microscopy after staining with DAPI. Quantitative estimation of extracellular DNA was performed using Sytox green. Mitochondrial ROS production with PPARγ agonist-treated/untreated neutrophils was detected using MitoSOX red. Pioglitazone and rosiglitazone induce significant NET formation in CGD patients. Our data clearly signify the effect of PPARγ agonists in induction of NET formation in CGD cases. Apart from the proposed experimental studies regarding the detailed mechanism of action, controlled trials could provide valuable information regarding the clinical use of pioglitazone in CGD patients as curative HSCT remains challenging in developing countries.

1 September 2021 in Molecular Immunology
Verified
Journal Article
Closed access
EKEsmat Karimi
Esmat Karimi
FMFatemeh Mahmoudian
Fatemeh Mahmoudian
SRSaúl Oswaldo Lugo Reyes
Saúl Oswaldo Lugo Reyes
UBUmair Ahmed Bargir
Umair Ahmed Bargir
MMManisha Madkaikar
Manisha Madkaikar
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani

25 February 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
ADAparna Dalvi
Aparna Dalvi
UBUmair Ahmed Bargir
Umair Ahmed Bargir
GNGita Natraj
Gita Natraj
ISIra Shah
Ira Shah
MMManisha Madkaikar
Manisha Madkaikar
The diagnosis and treatment of patients with mendelian susceptibility to mycobacterial disease (MSMD) pose consistent challenges due to the diverse infection spectrum observed in this population. Common clinical manifestations include Bacillus Calmette-Guérin vaccine (BCG) complications in countries where routine BCG vaccination is practiced, while in non-BCG-vaccinating countries, Non-Tuberculous Mycobacteria (NTM) is prevalent. In tuberculosis-endemic regions, Mycobacterium tuberculosis (MTB) has a high prevalence, along with other intracellular organisms. Isolating these organisms presents a significant challenge, and treatment is often initiated without confirming the specific species. This review primarily focuses on the methods and challenges associated with diagnosing and treating MSMD patients.

9 May 2023 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
VGVijaya Gowri
Vijaya Gowri
ACAkshaya Chougule
Akshaya Chougule
MGMaya Gupta
Maya Gupta
PTPrasad Taur
Prasad Taur
VIVaishnavi V. Iyengar
Vaishnavi V. Iyengar
MDMukesh M. Desai
Mukesh M. Desai